Catalog Products » Stable Cell Lines » Human Recombinant NK3 Tachykinin Receptor Stable Cell Line
CHO-K1/NK3 Stable Cell Line

Figure 1: Neurokinin B-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/NK3 cells. The cells were loaded with Calcium-4 prior to stimulation with an NK3 receptor agonist, Neurokinin B. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses (5-fold dilution) of Neurokinin B (Mean ± SD, n = 2). The EC50 of Neurokinin B on NK3 in CHO-K1 cells was 12 nM.
Note:
1. EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom)/ (1+10^ ((LogEC50-X)*HillSlope))
X is the logarithm of concentration.
Y is the response and starts at Bottom and goes to Top with a sigmoid shape.

CHO-K1/NK3 Stable Cell Line

Tachykinins are peptides sharing a common C-terminal amino acid sequence: Phe-X-Gly-Leu-Met-NH2. This neuropeptide family is composed of substance P, neurokinin A, and neurokinin B, which are widely distributed in mammalian central and peripheral nervous systems. These three molecules serve as both neurotransmitters and neuromodulators. Their actions are mediated by binding with three distinct receptors, namely NK1, NK2, and NK3. NK3 receptors show affinity for neurokinin B. They are predominantly expressed in both the peripheral and central nervous systems. NK3 receptors appear to modulate monoaminergic and amino acid neurotransmission. Studies show that manipulating modulation of NK3 receptor activity may have therapeutic utility in psychiatric diseases such as schizophrenia and affective disorders.
M00201
$8,500.00

Ask us a question
Description

Tachykinins are peptides sharing a common C-terminal amino acid sequence: Phe-X-Gly-Leu-Met-NH2. This neuropeptide family is composed of substance P, neurokinin A, and neurokinin B, which are widely distributed in mammalian central and peripheral nervous systems. These three molecules serve as both neurotransmitters and neuromodulators. Their actions are mediated by binding with three distinct receptors, namely NK1, NK2, and NK3. NK3 receptors show affinity for neurokinin B. They are predominantly expressed in both the peripheral and central nervous systems. NK3 receptors appear to modulate monoaminergic and amino acid neurotransmission. Studies show that manipulating modulation of NK3 receptor activity may have therapeutic utility in psychiatric diseases such as schizophrenia and affective disorders.

Synonyms

NK3 receptor, Neurokinin B receptor, Neurokinin B, neuromedin K, NK3R, Nmkr, neurokinin beta receptor, Tac3r, NK-3 receptor, NK-3R, Nkr, Neuromedin K receptor (Neurokinin B/Tachikin 3), neuromedin K receptor, neuromedin-K receptor, tachikin receptor 3, tachykinin receptor 3, SP-N receptor

Overview
Applications Functional assays for NK3 receptor

Product Introduction
Storage Liquid nitrogen immediately upon delivery
Species Human

Culture Conditions
Freeze Medium 45% culture medium, 45% FBS (Cat. #10099-141, Gibco), 10% DMSO (Cat. #D2650, Sigma)
Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 100 μg/ml Hygromycin B (Cat. # 10687010, Invitrogen)

Examples
  • CHO-K1/NK3 Stable Cell Line
  • CHO-K1/NK3 Stable Cell Line

    Figure 1: Neurokinin B-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/NK3 cells. The cells were loaded with Calcium-4 prior to stimulation with an NK3 receptor agonist, Neurokinin B. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses (5-fold dilution) of Neurokinin B (Mean ± SD, n = 2). The EC50 of Neurokinin B on NK3 in CHO-K1 cells was 12 nM.
    Note:
    1. EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom)/ (1+10^ ((LogEC50-X)*HillSlope))
    X is the logarithm of concentration.
    Y is the response and starts at Bottom and goes to Top with a sigmoid shape.


Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*